Pharmacological treatment of pulmonary arterial hypertension

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorAlmaghrabi, Abdullah
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intenzív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2018-11-19T12:31:10Z
dc.date.available2018-11-19T12:31:10Z
dc.date.created2018-04-13
dc.description.abstractPulmonary arterial hypertension (PAH), characterized by increased pulmonary vascular resistance and arterial pressure,Pulmonary vasoconstriction and associated remodeling of the vascular walls are thought to be involved in the initiation of pulmonary arterial hypertension (PAH), a pulmonary vascular disease that, if left untreated, can lead to heart failure and death,Pulmonary arterial hypertension (PAH) has evolved from a disease with limited treatment options to one where numerous therapies that target three key pathophysiological pathways in the disease (i.e. the prostacyclin, endothelin and nitric oxide pathways) are available (Humbert M et al., (2014)) All three pathways can now be targeted with approved drugs that significantly improve long- term outcomeshu_HU
dc.description.correctorhbk
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent48hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/259303
dc.language.isoenhu_HU
dc.subjectPulmonary arterial hypertensionhu_HU
dc.subjectpharmacological treatment of PAH
dc.subjectprostacyclin
dc.subjectendothelin
dc.subjectnitric oxide pathways
dc.titlePharmacological treatment of pulmonary arterial hypertensionhu_HU
Fájlok